INTU vs PFE: Which Is the Better Buy?

Side-by-side comparison of Intuit Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
Intuit Inc. · Technology
$396.57
+37.7% upside to fair value
High Conviction Grade A-
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
INTU has more upside to fair value (+37.7%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric INTU PFE
Current Price $396.57 $26.91
Fair Value Estimate $546.00 $35.00
Upside to Fair Value +37.7% +30.1%
Market Cap $110.4B $153.0B
Forward P/E 19.5x 9.5x
EV / EBITDA 19.0x 13.8x
Price / Sales 5.9x 2.4x
Price / FCF 18.1x 16.8x
Revenue Growth YoY +15.6% -1.6%
Gross Margin 80.8% 70.3%
Operating Margin 26.1% 24.7%
Return on Equity 19.6% 9.0%
Dividend Yield 1.17% 6.4%
FCF Yield 5.51% 5.9%
Analyst Consensus Buy Hold
Investment Thesis
INTU — Intuit Inc.
Intuit is a near-monopoly financial operating system for 60+ million American households and small businesses. TurboTax handles 40%+ of US e-filed returns; QuickBooks is so deeply embedded in SMB workflows it has become the default accounting standard. The stock has fallen 51% from its 2025 high as markets price in AI disruption that has not materialized at scale and may not, since tax complexity…
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric INTU PFE
Zone Low $410.00 $25.00
Zone High $464.00 $29.00
In Buy Zone? Yes Yes
← INTU Research    PFE Research →    All Research